Skip to search formSkip to main contentSkip to account menu
Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
TLDR
Treatment with lutetium‐177 (177Lu)–Dotatate resulted in markedly longer progression‐free survival and a significantly higher response rate than high‐dose octreotide LAR among patients with advanced midgut neuroendocrine tumors.
View on Wolters Kluwer
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
TLDR
This guidance covers the rationale, indications and contraindications for PRRNT, assessment of treatment response and patient follow-up, and is aimed at guiding nuclear medicine specialists in selecting likely candidates to receive PRR NT and to deliver the treatment in a safe and effective manner.
View on Springer
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
View on PubMed
ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
TLDR
The goal of this paper is to update a more extensive review and guidelines paper published in 2012 with any pertinent update pertaining to the diagnosis and staging of individual prima prima cancer patients.
View on PubMed
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
View on Elsevier
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
TLDR
The utility of CgA measurement in NETs is reviewed and its biological role and the clinical value of its measurement are described, showing some utility in predicting disease recurrence, outcome, and efficacy of therapy.
View on Springer
Everolimus for advanced pancreatic neuroendocrine tumors.
TLDR
Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events.
View on PubMed
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
View on Elsevier
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.
TLDR
While platinum-based chemotherapy is effective in NEC, it seems to have limited value in NET G3, which is characterized by significant differences in Ki-67 index and outcomes.
View on PubMed
ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
a Department of Surgery, Medical University of Vienna, Vienna , Austria; b Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Berlin ,…
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License